CheckMate 9DW, 8HW, NEST, and Bot/Bal
By Benjamin Weinberg, MD, FACP - Last Updated: January 27, 2025At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Benjamin Weinberg, MD, FACP, of the Lombardi Comprehensive Cancer Center, provided his perspective on the CheckMate 9DW expanded analyses in liver cancer, as well as multiple studies in colorectal cancer, including CheckMate 8HW and NEST, among others.
Advertisement
Post Tags:ASCO GI 2025: Focus on Liver Cancer
Advertisement
Related Posts
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Maen Abdelrahim reflects on the multidisciplinary collaboration required to make transplant oncology a clinical reality.
GI Oncology Now spoke with experts about HCC, how its management is changing, and how advancements are reshaping the disease.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.